Health Reform And Rare Diseases: Orphan Drugs May Do Well Amid Changes
Executive Summary
Advocates for patients with rare diseases are urging Congress to build in special considerations for treatments for rare diseases in several key provisions of health care reform
You may also be interested in...
FOBs Must Follow The Senate’s Health Reform Pathway; Placeholder Is Key
The state of the congressional debate on follow-on biologics legislation is probably best expressed by the first line on the topic from the most prominent bill: "[Policy under discussion].
Orphans Wanted: FDA Offers New Ideas For Rare Disease Drug Development
FDA's top review managers have a message for drug developers: they are eager to find creative ways to work with sponsors to bring new treatments for rare diseases to market
FOBs Must Follow The Senate’s Health Reform Pathway; Placeholder Is Key
The state of the congressional debate on follow-on biologics legislation is probably best expressed by the first line on the topic from the most prominent bill: "[Policy under discussion].